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Abstract: Idiosyncratic drug reactions (IDRs) are poorly understood, unpredictable, and 
not detected in preclinical studies. Although the cause of these reactions is likely multi-
factorial, one hypothesis is that an underlying inflammatory state lowers the tolerance to a 
xenobiotic. Previously used in an inflammation IDR model, bacterial lipopolysaccharide 
(LPS) is heterogeneous in nature, making development of standardized testing protocols 
difficult.  Here,  the  use  of  rat  tumor  necrosis  factor-α  (TNFα)  to  replace  LPS  as  an 
inflammatory stimulus was investigated. Sprague-Dawley rats were treated with separate 
preparations of LPS or TNFα, and hepatic transcriptomic effects were compared. TNFα 
showed enhanced consistency at the transcriptomic level compared to LPS. TNFα and LPS 
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regulated similar biochemical pathways, although LPS was associated with more robust 
inflammatory signaling than TNFα. Rats were then codosed with TNFα and trovafloxacin 
(TVX), an IDR-associated drug, and evaluated by liver histopathology, clinical chemistry, 
and gene expression analysis. TNFα/TVX induced unique gene expression changes that 
clustered separately from TNFα/levofloxacin, a drug not associated with IDRs. TNFα/TVX 
cotreatment  led  to  autoinduction  of  TNFα  resulting  in  potentiation  of  underlying  gene 
expression  stress  signals.  Comparison  of  TNFα/TVX  and  LPS/TVX  gene  expression 
profiles  revealed  similarities  in  the  regulation  of  biochemical  pathways.  In  conclusion, 
TNFα could be used in lieu of LPS as an inflammatory stimulus in this model of IDRs. 
Keywords: idiosyncratic hepatotoxicity; liver; inflammation; rat; transcriptomics 
Non-Standard  Abbreviations:  Idiosyncratic  drug  reaction  (IDR);  lipopolysaccharide 
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bilirubin (TBIL); principal component analysis (PCA); IFN (interferon); neutrophil (PMN); 
endoplasmic  reticulum  (ER);  reactive  oxygen  species  (ROS);  mitogen-activated  protein 
kinase  kinase  kinase  (MAP3Ks);  interleukin-12  (IL-12);  ataxia  telangiectasia-mutated 
(ATM) 
 
1. Introduction 
Idiosyncratic drug reactions (IDRs) represent a major threat to public health. These reactions are 
unpredictable,  not  readily  detected  in  preclinical  studies,  and  typically  not  uncovered  until  
post-marketing of a drug after exposure of a large cohort of patients [1]. Typically, IDRs occur in a 
small subset of patients and are reversible upon removal of the drug. However, in many cases, the 
drug-induced severe liver damage results either in the need for a liver transplant or in fatality. 
IDRs are likely the result of a complex interplay of genetic, environmental, and lifestyle factors [1]. 
Although unlikely to explain all IDRs, several hypotheses have been formulated for the mechanism(s) 
of these reactions. One such hypothesis postulates that a modest inflammatory episode can decrease the 
toxicity threshold of a drug, thus reducing its therapeutic index [2]. As such, drugs that are normally 
considered safe can cause significant adverse effects when associated with an inflammatory stimulus. 
This hypothesis was supported by the production of liver injury in rodent models in which bacterial 
lipopolysaccharide  (LPS)  was  coadministered  with  drugs  associated  with  hepatic  IDRs,  including 
diclofenac, ranitidine, chlorpromazine, sulindac, and trovafloxacin (TVX) [3–8]. 
The  fluoroquinolone  antibiotic,  TVX,  is  a  prototypical  idiosyncratic  hepatotoxicant  with  severe 
restrictions on its use [9]. Although TVX does not induce significant liver toxicity in rodents, it is toxic 
when coadministered with LPS as evidenced by increases in serum alanine aminotransferase activity 
(ALT) and hepatocellular necrosis [4,8]. Hepatic toxicogenomic analyses provide insight into toxic 
mechanisms [10], and these studies have shown that rats cotreated with TVX and LPS can be clearly Int. J. Mol. Sci. 2010, 11                       
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differentiated  from  those  treated  with  either  agent  alone,  or  cotreated  with  LPS  and  levofloxacin 
(LVX),  a  fluoroquinolone  antibiotic  not  associated  with  liver  toxicity  in  humans  [4].  These 
observations were confirmed in an LPS mouse model [8,11,12]. 
Although the rodent LPS/TVX models represent valuable research tools for in-depth mechanistic 
studies, their major shortcomings are related to the variability associated with the heterogeneous nature 
of LPS. The central domain of LPS consists of a glycolipid (lipid A) and a polysaccharide moiety, 
which can further be subclassified into a core oligosaccharide and an O-specific polysaccharide (OPS) 
[13].  This  OPS  substituent  can  have  long  polysaccharide  repeats  with  a  variety  of  possible 
monosaccharide components, resulting in significant structural and biological diversity among bacterial 
species and preparations of LPS. As a consequence, the use of LPS as a principal inflammagen requires 
time-consuming, dose range finding studies and makes it difficult to develop a standardized protocol. 
In an attempt to establish a standardized protocol for this model of IDRs, we evaluated a surrogate 
modulator of inflammation, tumor necrosis factor-α (TNFα), to replace LPS. TNFα is a member of a 
superfamily  of  inflammatory  mediators  involved  with  immunogenic  responses  to  a  variety  of 
pathogens [14]. The cellular functions of TNFα are diverse and include activation of apoptosis via 
“death receptors”, initiation of an inflammatory signal partially by influencing the conformation of 
adhesion  molecules,  cell  proliferation  and  differentiation,  and  protection  from  infection  [15].  Its 
endogenous regulation is complex and involves a myriad of cell types, predominantly macrophages, 
Kupffer cells, T-cells, and neutrophils for its production and effects. This cytokine can be produced as 
a recombinant protein with homogenous composition.  
In the LPS/drug models studied thus far, TNF activation appears to be a critical, proximal event in 
initiating a cascade of downstream inflammatory events that ultimately result in hepatocellular necrosis 
[16,17]. Indeed, cotreatment of mice with TNFα and TVX resulted in liver injury similar to that seen 
after coadministration of LPS and TVX [17]. Replacement of LPS with TNF might avoid variability 
due to the marked differences in biological activity associated with LPS preparations. Accordingly, the 
present study focused on the evaluation of rat recombinant TNFα compared to LPS, both alone and in 
combination  with  TVX.  Specifically,  the  objectives  were  (1)  to  compare,  in  rats,  the  hepatic 
transcriptomes  induced  by  treatment  with  LPS  or  TNFα,  (2)  to  evaluate  toxicity  induced  by 
combination  dosing  using  TNFα/TVX  or  TNFα/LVX,  and  (3)  to  compare  the  effects  induced  by 
TNFα/TVX versus LPS/TVX. 
2. Results and Discussion  
2.1. Results 
2.1.1. Serum Chemistry and Histopathology for the TNFα Study 
TNFα treatment (0.01 mg/kg i.v.) resulted in no evidence of acute liver injury after 6 hours exposure 
in three separate studies (3 rats per study; total n = 9 rats) using 3 different lots of TNFα. No significant 
changes in liver enzyme activities (ALT, AST, GGT, ALP) were evident. No histologic changes were 
identified in the liver. Int. J. Mol. Sci. 2010, 11                       
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2.1.2. Comparison of Hepatic Transcriptomes Induced by LPS or TNF 
TNFα treatment resulted in extensive (~2700) global liver transcriptomic changes. These changes 
were consistent among individual studies, lot numbers, and animals (Figure 1A, B) as evidenced by 
hierarchical cluster analysis and principal component analysis (PCA) of individual global expression 
profiles. The heatmap in Figure 1A shows that the profiles from two separate preparations of TNFα 
were indistinguishable from a third preparation. Using PCA, the liver profiles from all TNFα-treated 
rats were localized into one cluster, suggesting a high degree of similarity between the three lots with 
low inter-individual variability (Figure 1B). A complete listing of gene expression changes is presented 
in supplemental Table 1. 
Figure 1. (A) Comparison of the hepatic gene expression profiles for LPS- or TNFα-treated 
rats using separate lots of each agent. Individual probe sets (genes) are displayed on the 
horizontal axis and each individual treatment is on the vertical axis. Shades of red indicate 
increased expression relative to the vehicle (Veh) treatment, and shades of green indicate 
decreased expression. Black indicates no statistically significant change in expression. Both 
the genes and experiments were analyzed using divisive hierarchical cluster analysis with 
Euclidean distance as the similarity measure. The dendogram shows relative similarities 
between  the  individual  expression  profiles.  Statistical  filters  were  applied  using  |fold 
change| ≥ 2.0 and p  0.01 in at least one rat. Number of probe sets represented in each 
heatmap is TNFα (~2700) and LPS (~5600). Lot designations: TNF Lot #1 (098K1865); 
TNF Lot #2 (126K1053); TNF Lot #3 (087K1290); LPS Lot #1 (51K4115); LPS Lot #2 
(024K4067). (B) Principal component analysis (PCA) of liver gene expression profiles for 
all TNFα-treated and LPS-treated rats. Three principal components were generated and 
plotted for each expression profile (|fold change| ≥ 2.0 and p  0.01) using Rosetta Resolver 
software. Treatments that clustered together are represented within the same oval. 
A                                 B 
   
LPS treatment also induced a large number of gene expression changes (~5600). Unlike TNFα, the 
LPS  lots  induced  different  transcriptomic  responses  (Figure  1A,  B).  In  particular,  PCA  clustering 
separated the expression profiles based on the lot of LPS used in each study. Individual animals dosed Int. J. Mol. Sci. 2010, 11                       
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with the same lot of LPS displayed little variability, indicating that the major component of variation 
was due to LPS lot differences rather than inter-individual variation. It should be noted that these 
studies were conducted independently, which may also contribute to variability. Although these gene 
expression variations were evident, LPS did not result in significant liver injury (as measured by serum 
chemistry and histopathology) in either study at the early time evaluated (t = 4 h). The clusters resulting 
from the expression profiles of LPS-treated rats (Figure 1B) were distinct from those treated with 
TNFα, and the overall number of expression changes was much greater than those induced by TNFα. 
The Venn diagram in Figure 2 illustrates the large number of LPS-induced expression changes. Of 
these, 16% overlapped with TNFα-induced changes, but the majority of the LPS changes were distinct. 
In contrast, 54% of the TNFα-induced transcriptional changes overlapped with those induced by LPS. 
Figure 2. Venn diagram comparing the liver gene expression changes induced by TNFα or 
LPS treatment (|fold change| ≥ 2.0 and p  0.05). Individual gene expression changes were 
combined in silico for this comparison. 
631 731 3949
TNF
LPS
631 731 3949
TNF
LPS
 
2.1.3. Classification of Biochemical Pathways Significantly Impacted by LPS or TNFα 
Classification  of  genes  into  their  corresponding  biochemical  pathways  can  give  insight  into 
underlying biological function. Individual hepatic gene expression profiles from LPS or TNFα-treated 
rats were combined in silico to reduce inter-individual variability and to increase stringency, and these 
genes were classified and ranked into the corresponding pathways. The analysis separated the pathways 
into those perturbed by both LPS and TNFα (Figure 3A, B) and by those changed solely by each 
respective agent (Figure 3C, D). For those impacted by both LPS and TNFα (i.e., mostly driven by the 
731  overlapping  genes  shown  in  Figure  2),  most  of  the  pathways  were  involved  with  various 
immunological processes. However, there were differences in the magnitude of perturbation by each 
treatment. For LPS, ER-stress response and interferon signaling ranked highest (~40–50%) followed by 
multiple immune and cytokine pathways with impact values >20% (most genes were upregulated). For 
TNFα, similar immune pathways were impacted, but they differed in rank ordering with lower percent 
impact and included more downregulated genes (Figure 3B, D). Besides immune and inflammatory 
responses, LPS and TNFα perturbed pathways involved with various stress response signals, including 
those involved with stellate cell activation and hepatic cholestasis. 
Whereas expression changes after treatment with LPS or TNFα exhibited many similarities, the 
overall pathway impact resulting from LPS treatment was more robust and extensive (increased percent Int. J. Mol. Sci. 2010, 11                       
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perturbation), consistent with the Venn analysis. Several pathways perturbed uniquely by LPS were 
involved with apoptotic and death receptor signaling. These results suggest that LPS has a greater 
effect  overall  compared  to  TNFα  on inflammation signals  in  liver at  the doses and the timepoint 
evaluated. 
Figure 3. Results of Ingenuity Pathway Analysis for rats treated with either LPS or TNF. 
Ingenuity  software  was  applied  to  classify  the  top  pathways  that  were  impacted  after 
treatment. To account for inter-individual variability, gene expression profiles from each 
TNFα- or LPS-treated rat were combined in silico using Resolver software. From these 
combined  groups,  genes  with  |fold  change|  ≥  2.0  and  p    0.05  were  evaluated  in  the 
pathway analysis. Pathways were separated into those perturbed by both LPS and TNFα 
(Panel A/B) and by those changed uniquely by each respective agent (Panel C/D). Pathway 
names  are  listed  on  the  y-axis  and  percent  impact  is  listed  on  the  x-axis. Each bar is 
subdivided  to  indicate  the  relative  percentage  of  upregulated  (red)  vs.  downregulated 
(green) genes. P-values were also generated as indicated by the black line using the entire 
array as the background set. (A) Pathway analysis of the genes differentially expressed in 
the liver upon treatment of rats with LPS: these pathways were also changed by treatment 
with  TNFα.  The  731  overlapped  genes  (Figure  2)  are  the  major  component  of  these 
pathway changes. (B) Pathway analysis of the genes differentially expressed in the liver 
upon treatment of rats with TNFα: these pathways were also changed by treatment with 
LPS (panel A). Since these pathways were also impacted by LPS, they are listed in the 
same order as panel A for ease of comparison. (C) LPS-specific pathways were identified 
for the genes differentially expressed in the liver. These pathways were not perturbed by 
TNFα. The 3949 LPS-specific genes (Figure 2) are the major component of these pathway 
changes.  (D).  TNFα-specific  pathways  were  also  identified  for  the  genes  differentially 
expressed in the liver. These pathways were not perturbed by LPS. The 631 TNFα-specific 
genes (Figure 2) are the major component of these pathway changes. 
A                                              B 
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Figure 3. Cont. 
C                                            D 
   
2.1.4. Evaluation of Fluoroquinolone Toxicity after TNFα Coadministration 
Rats given TNFα alone, TVX alone, LVX alone, or any combination of TNFα and fluoroquinolone 
showed no significant changes in serum chemistry, and there were no significant liver histopathology 
findings (data not shown).  
Figure 4. (A) Hierarchical cluster analysis of hepatic gene expression profiles induced by 
cotreatment with the following agents: Veh/TVX, Veh/LVX, TNFα/Veh, TNFα/LVX, or 
TNFα/TVX.  TNFα/drug  cotreatment  was  completed  with  only  one  TNFα  lot  (see 
Experimental Section). The dendrogram indicates that the TNFα/TVX treatment is unique 
compared to all other groups. Statistical filters were applied using |fold change| ≥ 2.0 and  
p  0.01. (B) A Venn diagram overlapping the gene expression profiles induced in the liver 
of  rats  by  TNFα/TVX,  TNFα/LVX,  and  TNFα/Veh.  Stringent  gene  filtration  criteria  
(|FC| ≥ 1.5 & p  0.05 in 2 of 3 rats) were used to remove genes with high biological 
variation. The TNFα/TVX treatment uniquely regulated the largest number of genes (679). 
A                                 B 
 
TVX or LVX alone induced few (~300–500) gene expression changes (|fold change| ≥ 2; p  0.01), 
suggesting a minor impact on overall liver homeostasis (Figure 4A). Treatment with TNFα/LVX or Int. J. Mol. Sci. 2010, 11                       
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TNFα/TVX resulted in a pronounced increase in hepatic gene expression changes (~2500 and 3500 
respectively for each co-dose) relative to treatment with TNF or either agent alone. Cluster analysis 
indicated that the TNFα/TVX-induced expression profiles were significantly different from those of all 
other  treatment  groups.  For  the  livers  from  TNFα/TVX-treated  rats,  rigid  selection  criteria 
distinguished 679 probe sets that were uniquely regulated (Figure 4B). This subset of genes included 
the  neutrophil  (PMN)  chemokines,  CINC-1  (~40-fold  increase)  and  MIP-2  (~7-fold  increase)  
(Figure 5A), which were previously reported to be increased in the LPS/TVX model of hepatotoxicity 
[4]. In contrast, TNFα alone and TNFα/LVX treatments regulated <~100 probe sets. 
Interestingly, TNFα/TVX treatment resulted in a marked autoinduction of TNFα expression, which 
was not observed in any other treatment group (Figure 5B). TNFα overstimulation was also reflected in 
an extensive induction of downstream signaling members of the TNFα cascade (Figure 6). In contrast, 
this pathway was not affected in livers from TNFα/LVX treatment (data not shown). 
Figure 5. (A) Comparison of the relative mRNA expression for the neutrophil chemokines 
(MIP2  and  CINC1).  Each  bar  represents  treatment  with  Veh,  TVX,  or  LVX  and 
cotreatment with either Veh or TNFα. The y-axis represents fold change of mRNA level vs. 
vehicle.  The  expression  profiles  from  each  individual  rat  were  pooled  in  silico  using 
Rosetta Resolver software (gene expression change p < 0.05) to account for inter-animal 
variation. Error bars represent standard deviation. * Significantly different from Veh/Veh 
and  TNFα/Veh  (p  <  0.05);  #  Significantly  different  from  Veh/Veh;  **  Significantly 
different from Veh/Veh, but not from TNFα/Veh; ## Significantly different from Veh/Veh 
and TNFα/Veh.  (B)  Quantitation  of endogenous  hepatic TNFα mRNA with or without 
exposure to exogenous TNFα protein. Labels and inter-animal variation are the same as in 
panel  A.  TNFα/TVX  treatment  shows  a  large  autoinduction  of  TNFα  mRNA.  * 
Significantly different from Veh/Veh, TNFα/Veh, TNFα/LVX (p < 0.05); ** Significantly 
different from Veh/Veh. 
A 
 
B 
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Figure 6. Effect of TNFα autoinduction on the expression of members downstream from 
TNFα signal transduction. Pathway diagram was generated using Ingenuity software. Each 
pathway  member  labeled  in  red  or  green  represents  upregulation  or  downregulation, 
respectively. White represents no significant change in expression. TNFα/TVX showed a 
large degree of downstream activation in contrast to TNFα/LVX (data not shown). 
 
2.1.5. Comparison of Gene Expression Profiles Induced by TNFα/TVX and LPS/TVX 
Gene expression profiles from the livers of TNFα/TVX-treated rats formed a unique cluster relative 
to rats treated with TNFα alone and to TNFα/LVX-treated rats, a result similar to the pattern observed 
with LPS/TVX treatment. Upregulation of PMN chemokines (CINC-1 and MIP2) was similar between 
the TNFα and LPS models, but LPS/TVX did not induce TNFα over LPS alone (Figure 5B). 
In Tables 1–3, a rank ordering (as determined by Ingenuity Pathways software) was completed for 
the top (p < 0.06) biochemical pathways impacted by the unique gene expression changes induced by 
TNFα/TVX  and/or  LPS/TVX  cotreatment,  but  not  by  each  drug,  TNFα,  or  LPS  alone.  Of  these,  
11 pathways were impacted similarly by TNFα/TVX and LPS/TVX cotreatments (Table 1), including 
tight junction networks, fMLP signaling in PMNs, IL-12 signaling, and p53 signals. Some notable 
pathways impacted only by TNFα/TVX (Table 2) included ATM signaling, hypoxia signaling, cell 
cycle control, NF-B signaling, cytokine signaling, and response to ROS. Finally, unique pathways 
changed  only  in  livers  from  LPS/TVX-cotreated  rats  (Table  3)  included  MAPK  signals,  cytokine 
communication, mitochondrial dysfunction, PDGF signaling, toll-like receptor, and mRNA processing. 
Although  there  were  several  specific  pathway  differences  between  the  two  treatment  groups,  the 
overall  function/theme  of  many  pathways  overlapped,  which  suggested  a  similar  innate  immune 
system-enhancing effect from the presence of TVX after pretreatment with either LPS or TNFα. Int. J. Mol. Sci. 2010, 11                       
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Table 1. List of Biochemical Pathways Regulated in Common Between TNFα/TVX and 
LPS/TVX. 
Both TNFα/TVX & LPS/TVX 
Pathway Name 
TNF/TVX % 
Impact 
TNF/TVX  
P-Value 
LPS/TVX % 
Impact 
LPS/TVX  
P-Value 
Tight Junction Signaling  26.1%  0.001  18.5%  0.021 
MIF Regulation of Innate Immunity  33.3%  0.003  22.2%  0.039 
Dendritic Cell Maturation  25.3%  0.004  20.0%  0.013 
NFAT Regulation of Immune Response  24.4%  0.011  17.9%  0.058 
fMLP Signaling in Neutrophils  26.2%  0.013  19.7%  0.051 
IL-12 Signaling in Macrophages  23.9%  0.018  20.9%  0.014 
Glucocorticoid Receptor Signaling  20.5%  0.021  17.9%  0.012 
p53 Signaling  22.0%  0.025  22.0%  0.004 
B Cell Receptor Signaling  20.5%  0.040  18.2%  0.023 
Role of Macrophages, Fibroblasts and 
Endothelial Cells in RA  18.3%  0.040  17.6%  0.005 
Molecular Mechanisms of Cancer  17.8%  0.044  14.9%  0.043 
Table 2. List of Biochemical Pathways Regulated by TNFα/TVX, but not by LPS/TVX. 
TNFα/TVX 
Pathway Name  % Impact  P-Value 
ATM Signaling  34.4%  0.001 
Hypoxia Signaling in the Cardiovascular System  32.0%  0.001 
Cell Cycle: G2/M DNA Damage Checkpoint Regulation  37.0%  0.002 
CD28 Signaling in T Helper Cells  27.9%  0.003 
HMGB1 Signaling  27.0%  0.004 
Role of PKR in Interferon Induction and Antiviral Response  32.3%  0.006 
Androgen Signaling  26.1%  0.007 
Activation of IRF by Pattern Recognition Receptors  27.8%  0.008 
NF-κB Signaling  23.8%  0.009 
IL-10 Signaling  27.5%  0.010 
CD27 Signaling in Lymphocytes  27.3%  0.010 
p38 MAPK Signaling  24.2%  0.012 
4-1BB Signaling in T Lymphocytes  31.8%  0.013 
Death Receptor Signaling  25.0%  0.017 
Cholecystokinin/Gastrin-mediated Signaling  24.2%  0.024 
iCOS-iCOSL Signaling in T Helper Cells  24.5%  0.025 
Relaxin Signaling  23.5%  0.025 
Role of BRCA1 in DNA Damage Response  25.0%  0.026 
Role of RIG1-like Receptors in Antiviral Innate Immunity  27.3%  0.026 
Production of Nitric Oxide and ROS in Macrophages  21.5%  0.028 
ILK Signaling  21.1%  0.031 
 
 Int. J. Mol. Sci. 2010, 11                       
 
 
4707 
Table 2. Cont. 
TNFα/TVX 
Pathway Name  % Impact  P-Value 
Cdc42 Signaling  21.4%  0.040 
Angiopoietin Signaling  25.0%  0.042 
AMPK Signaling  23.8%  0.045 
Pattern Recognition Receptors in Bacteria/Virus  20.5%  0.046 
Phospholipase C Signaling  17.9%  0.049 
Hepatic Cholestasis  19.8%  0.050 
Protein Kinase A Signaling  18.5%  0.060 
B Cell Activating Factor Signaling  24.0%  0.062 
Table 3. List of Biochemical Pathways Regulated by LPS/TVX, but not by TNFα/TVX. 
LPS/TVX 
Pathway Name  % Impact  P-Value 
Chronic Myeloid Leukemia Signaling  23.1%  0.006 
LPS-stimulated MAPK Signaling  25.5%  0.006 
PDGF Signaling  23.4%  0.017 
Communication between Innate and Adaptive Immune Cells  25.0%  0.018 
PPAR Signaling  21.9%  0.019 
VDR/RXR Activation  23.1%  0.026 
Cytokines in Mediating Communication between Immune Cells  31.2%  0.028 
Toll-like Receptor Signaling  20.0%  0.031 
GM-CSF Signaling  24.4%  0.032 
Cleavage and Polyadenylation of Pre-mRNA  37.5%  0.034 
Fc Epsilon RI Signaling  19.6%  0.039 
Cell Cycle: G1/S Checkpoint Regulation  20.5%  0.044 
Estrogen Receptor Signaling  18.2%  0.046 
T Cell Receptor Signaling  18.9%  0.049 
CD40 Signaling  21.1%  0.051 
Wnt/β-catenin Signaling  17.4%  0.051 
PI3K/AKT Signaling  18.3%  0.056 
TREM1 Signaling  21.9%  0.056 
Regulation of eIF4 and p70S6K Signaling  19.1%  0.058 
Mitochondrial Dysfunction  17.6%  0.062 
Cell Cycle Regulation by BTG Family Proteins  25.0%  0.063 
2.2. Discussion 
One proposed mechanism to explain some IDRs is that a mild underlying inflammatory stimulus 
lowers the therapeutic index for an otherwise safe drug [2]. Although this mechanism is unlikely to 
explain all IDRs, background information on a compound’s potential to exacerbate inflammation may 
be  useful  toward  risk  assessment  of  compounds  in  preclinical  development.  Currently,  the  most 
characterized inflammatory agent used to address the proposed mechanism is LPS [2,4,16]. LPS is a Int. J. Mol. Sci. 2010, 11                       
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potent  activator  of  the  immune  system  and  leads  to  a  massive  stimulation  of  gene  transcription, 
especially in the bone marrow, spleen, and liver [18]. 
LPS is a useful inflammagen for mechanistic evaluation of drugs with known liabilities. However, 
the heterogeneous nature of LPS renders difficult the establishment of a standardized test protocol. 
Gene expression profiling confirmed that different preparations of LPS caused significantly different 
hepatic transcriptomic responses that were not attributable to individual animal variation. In contrast, 
TNFα resulted in remarkably consistent transcriptomic profiles regardless of preparation. Therefore, 
replacing LPS with TNFα could provide a model with enhanced reproducibility, reducing the need for 
extensive dose range finding studies. 
In previous model characterizations, acute exposure to LPS at the doses used resulted in no overt 
liver injury [4]. Likewise, acute dosing with TNFα yielded no significant changes in serum chemistry 
or histology under these experimental conditions despite a clear signal at the level of transcription. The 
lack of a phenotypic effect  is  likely due to the acute dosing period (<6 h) and to the small  dose 
administered. Both proinflammatory agents induced similar changes in several cell signaling networks, 
especially those related to innate immune response pathways. However, the LPS effects were broader, 
as  evidenced  by  the  greater  number  of  pathways  impacted  and  a  more  pronounced  level  of  
gene regulation. 
LPS and other bacterial products mediate their effects partly via stimulation of toll-like receptors 
(TLRs), resulting in signal transduction and synthesis of various immune activators, such TRAF and 
NF-B [19]. This results in rapid mobilization of immune mediators to the primary infection sites. LPS 
itself, via activation of receptors such as TLR4, mediates signaling to downstream MAP3Ks, which in 
turn are essential for secretion of native TNFα and for the subsequent innate immune response [20,21]. 
TNFα  biosynthesis  results  from  LPS  stimulation  of cells,  and this  cytokine mediates  some of the 
effects  produced  by  LPS.  However,  LPS  stimulates  activation  of  additional  immune  mediators, 
including IL-6 [22], IL-12 [23], MCP-1 [24], and IL-8 [25]. Therefore, the enhanced perturbation of 
gene expression by LPS relative to TNFα is not surprising. 
Globally, TNFα/TVX treatment resulted in greater changes in the liver transcriptome compared to 
TNFα/LVX, despite the fact that LVX was administered at a 5-fold greater dose (comparable to the 
fold-difference in doses used clinically). From the TNFα/TVX group, genes involved with NF-B 
activation  such  as  RELA  and  TRAF2  were  significantly  induced.  NF-B  activation  occurs  as  a 
response to inflammatory stimuli and is integrally linked to TNFα signaling [26] TRAF2 regulates 
these signals via ubiquitin ligation to its targets (IB), which releases NF-B to exert its effects [27]. 
All of these perturbations were absent in the TNFα/LVX unique gene set, suggesting that the ability of 
TVX to potentiate an innate immune response is not shared by LVX. This supports the feasibility of 
evaluating novel drug development candidates for their ability to enhance an underlying inflammatory 
stimulus. Evaluation of additional IDR-inducing molecules would aid in the validation of such a model. 
TNFα, acting through its receptors (TNFR1 and TNFR2), is a critical mediator for manifestation of 
TVX hepatotoxicity in LPS-treated mice [8,28]. Indeed, cotreatment with TNF and TVX produced 
liver injury in mice [17]. Gene array data might facilitate elucidation of key mechanism(s) in this 
interaction. Furthermore, data from mice further support the choice of TNFα itself as an appropriate 
external inflammatory stimulus for these rodent models. Int. J. Mol. Sci. 2010, 11                       
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Also critical to the evaluation of the use of TNFα in lieu of LPS were the comparisons between 
TNFα/TVX and LPS/TVX responses. Unlike the mouse, there was no evidence of overt liver toxicity 
following TNFα/TVX administration at the early timepoint evaluated. The lack of a phenotypic effect 
at this early timepoint may reflect on the inability of TNFα to activate inflammatory signal transduction 
to the same extent as LPS in rats. The lack of an overt signal in rat may also suggest that mice are a 
more sensitive species to a TNFα/TVX interaction. For interpretation of gene expression data, early 
timepoints  offer  the  advantage  of  enhanced  insight  into  potential  primary  mechanisms  of  action. 
Indeed, genome-wide mRNA profiling of livers from TNFα/TVX-treated rats suggested a remarkable 
similarity in mode of action when compared to LPS/TVX in rats. More specifically, TNFα/TVX and 
LPS/TVX treatment perturbed similar immunological and stress response pathways, thus suggesting, 
despite differences in signaling robustness with no visible early injury, that treatment with LPS or 
TNFα ultimately led to similar toxicogenomic outcomes. Robust gene expression signals, such as those 
observed with TNFα/TVX treatment, are considered predictive of subsequent injury [10]. In addition, 
although  a  number  of  specific  pathways  did  overlap  between  TNFα/TVX  and  LPS/TVX,  a  more 
important factor may be that TNFα/TVX cotreatment activates the necessary/key pathways that may 
contribute to liver pathogenesis. 
Coadministration of TNFα/TVX resulted in  marked autoinduction of TNFα mRNA, which was 
absent upon exposure to TNFα alone or TNFα/LVX. Transactivation of factors downstream of the 
TNFα receptor substantiated this observation for the TNFα/TVX-cotreated rats. Autoinduction could 
potentially perpetuate inflammatory cascades and immune cell activation. Indeed, in the mouse model, 
there is evidence for dysregulated amplification cycles in which TNFα enhances expression of other 
inflammatory cytokines, leading to further TNFα production [17]. This could eventually augment the 
presence of deleterious factors resulting in toxicity. In mice, TVX has been shown to be a critical 
mediator  of  hepatotoxicity  at  least  partially  through  sustained  TNFα  signaling  [17].  TNFα/TVX 
cotreatment primarily reduced the clearance of endogenous serum TNFα with a relatively smaller effect 
of increased production. This was a rare example of a xenobiotic reducing systemic clearance of a 
cytokine. In that mouse study, mRNA expression of hepatic TNFα was not evaluated. Here, using gene 
expression analysis, we showed that enhanced expression in liver represents one source of increased 
TNFα  in  serum.  Interestingly,  hepatic  gene  expression  of  TNFα  was  not  elevated  in  livers  of 
LPS/TVX–treated animals compared to those treated with LPS alone, suggesting that other factors also 
contribute to the toxicity. However, we cannot exclude the possibility that the failure to observe an 
influence of TVX on TNFα expression in LPS-cotreated rats was due to pharmacokinetic differences, 
i.e.,  differences  in  the  time  of  initial  TNFα  exposure  relative  to  sacrifice  time  in  the  LPS-  and  
TNFα-cotreated groups. 
The exact mechanism responsible for the TVX-induced autoinduction of TNFα is unknown and 
requires  further  investigation.  Understanding  this  mechanism  could  lead  to  further  insight  into 
understanding TVX-induced hepatotoxicity since inflammatory mediators have been clearly linked to 
certain hepatotoxicities [29]. Relatively few reports exist describing this autoinduction effect. TNFα 
increases its own expression in some in vitro systems like human ZR-75-1 breast cancer cells [30] and 
rat  tracheal  epithelial  cells  [31].  In  HL60  leukemia  cells,  autoinduction  of  TNFα  required 
phospholipase A2 and lipoxygenase activity with subsequent release of arachidonic acid metabolites Int. J. Mol. Sci. 2010, 11                       
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[32]. In the present study, phospholipase A2 activating protein (Plaa) mRNA was overexpressed in the 
TNFα and TNFα/TVX treated rats, but was not consistently increased in the TNFα/LVX group. No 
change was observed in lipoxygenase expression, but phospholipase A1 (Pla1a) was increased in all 
rats treated with TNFα either alone or in combination with TVX or LVX. 
3. Experimental Section  
3.1. Administration of TNFα and Fluoroquinolone Drug 
All animal experiments for this study were conducted in accordance with the Guiding Principles in 
the Use of Animals in Toxicology (Anonymous 2002) and were approved by Abbott’s Institutional 
Animal  Care  and  Use  Committee  (IACUC).  Male  Sprague-Dawley  rats  [Crl:CD
®(SD)IGS  BR], 
weighing ~250 g at study initiation were obtained from Charles River Laboratories, Inc. (Wilmington, 
MA).  Rats  were  housed  singly  in  ventilated,  stainless  steel,  wire-bottom  hanging  cages  and  fed  
non-certified Rodent Chow (Harlan Labs, Madison, WI) and water ad libitum.  
After 24 h fasting, the rats were injected with recombinant rat TNFα (Sigma Chemical, St Louis, 
MO; lot numbers 126K1053, 087K1290, or 098K1865) via tail vein (i.v.) at a dose of 0.01 mg/kg body 
weight with a delivery volume of 1 mL/kg. This dose of TNFα was based on rat studies contained in 
the DrugMatrix database [33]. For the lot comparison analysis, TNFα was given in separate studies 
which were conducted several months apart. Two hours after TNFα administration, rats were treated 
(i.v.) with TVX (30 mg/kg), LVX (150 mg/kg) or vehicle (dextrose 5% in water with 0.1 N equivalent 
HCl) in a volume of 5 mL/kg. The previous LPS rat model served as a basis for dose selection with a 
lower TVX dose due to formulation restriction [4]. Treatment nomenclature was designated as follows: 
Veh/Veh (n = 3), TNFα/Veh (n = 9), Veh/TVX (n = 3), Veh/LVX (n = 3), TNFα/TVX (n = 3), and 
TNFα/LVX (n = 3). TNFα (lot #126k1053) was used for coadministration with TVX and LVX. Four 
hours after the second treatment, the rats were sacrificed using CO2 anesthesia and blood was collected. 
A portion of the liver was flash frozen in liquid nitrogen, and the remaining liver was preserved in 10% 
neutral-buffered  formalin.  One  TNFα/LVX  rat  was  misdosed  and  was  therefore  excluded  from  
further analysis. 
3.2. Administration of LPS 
Two different lots of LPS were used to compare hepatic gene expression changes. These studies 
were conducted at Michigan State University (MSU, East Lansing, MI) using a protocol similar to that 
previously described [4]. Rats received humane care according to the criteria outlined in the Guide for 
the Care and Use of Laboratory Animals (1996) prepared by the National Academy of Sciences, and 
procedures were approved by the Michigan State University Committee on Animal Use and Care. Male 
Sprague-Dawley rats [Crl:CD (SD)IGS BR; Charles River, Portage, MI] (n = 5) weighing 250–350 g 
were used for these studies. Animals were fed standard chow (rodent chow/Tek 8640; Harlan Teklad, 
Madison, WI) and allowed access to water ad libitum. In one study, LPS derived from Escherichia coli 
serotype  O55:B5  with  an  activity  of  9.2  ×   10
6  EU/mg  was  used  (catalog  number  L-2880,  Lot 
024K4067; Sigma-Aldrich, Inc., St. Louis, MO), designated in Figure 1 as Lot #2. This activity was 
determined using a QCL Chromogenic LAL Endpoint Assay from Cambrex (East Rutherford, NJ). Int. J. Mol. Sci. 2010, 11                       
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Rats fasted for 24 h were given 44.4 ×  10
6 EU/kg LPS or its saline vehicle (Veh) i.v., and food was 
then returned. Two hours later, vehicle (50/50 sterile saline/sterile water) was administered i.v. Two 
hours  later,  rats  were  anesthetized  with  sodium  pentobarbital  (75  mg/kg  i.p.)  and  euthanized  by 
exsanguination. The right medial lobe of the liver was flash-frozen in liquid nitrogen for subsequent 
gene expression analysis. For Lot #1 in Figure 1 (Lot 51K4115), data files were used from a previously 
published study [34] in which rats were treated with LPS (from E. Coli, serotype 055:B5) and vehicle 
using the same dose (44.4 ×  10
6 EU/kg LPS) and treatment protocol as described for Lot #2. 
3.3. Serum Chemistry and Histopathology for the TNFα Study 
Serum clinical chemistry parameters for the TNFα study were quantified using an Aeroset Clinical 
Chemistry Analyzer (Abbott Laboratories, Abbott Park, IL) and included: alanine amino transferase 
(ALT),  aspartate  amino  transferase  (AST),  gamma  glutamyltransferase  (GGT),  and  alkaline 
phosphatase (ALP) activities. Formalin-fixed liver samples (left and right lobes) were embedded in 
paraffin and sections (6 m) were stained with hematoxylin and eosin. 
3.4. RNA Preparation 
Frozen liver samples (approximately 100 mg of tissue per sample) were immediately added to 2 mL 
of  QIAzol  reagent  (Qiagen,  Valencia, CA)  and homogenized using a Polytron 300D homogenizer 
(Brinkman  Instruments,  Westbury,  NY).  One  mL  of  the  tissue  homogenate  was  transferred  to  a 
microfuge  tube,  and  total  RNA  was  extracted  via  chloroform  extraction  followed  by  nucleic  acid 
precipitation with isopropanol. The pellet was washed with 80% ethanol and resuspended in molecular 
biology  grade  water.  Nucleic  acid  concentration  was  determined  by  O.D.  260  nm  (Smart-Spec;  
Bio-Rad Laboratories, Hercules, CA), and RNA integrity was evaluated using a bioanalyzer (model 
2100; Agilent Technologies, Foster City, CA).  
3.5. Gene Array Analysis 
Microarray analysis of rat liver samples was performed using the standard protocol provided by 
Affymetrix, Inc. (Santa Clara, CA) as previously described [4] using Affymetrix Rat Genome RAE 
230_2.0 or RAE230A arrays containing ~31,000 or ~15,000 probe sets (genes) respectively. Resolver 
software  (Version  7.2;  Rosetta  Informatics,  Seattle  WA)  was  used  to  analyze  the  microarray data 
(available  in  supplemental  Table  1).  Ingenuity  Pathways Analysis software (Version 8.0 Ingenuity 
Systems, Redwood City, CA) was applied for pathway evaluations. For TNFα/TVX comparisons to 
LPS/TVX, the original data files from the previous LPS/TVX study were used [4].  
3.6. Statistics and Pathway Analysis 
Clinical  pathology  parameters  and  mRNA  fold  changes  were  analyzed  by  analysis  of  variance 
(ANOVA) with Tukey's post hoc test using GraphPad Prism software (Version 5; La Jolla, CA). The 
criterion  for  significance  was  p  ≤  0.05.  For  hepatic  microarray  analysis,  the  scanned  image  and 
intensity files (.cel files) were imported into Resolver software. Gene expression ratios were built for 
each drug-treated animal versus the respective vehicle-treated animals combined in silico using the Int. J. Mol. Sci. 2010, 11                       
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Resolver error model. All hierarchical cluster and principal component analyses were completed with 
Resolver software. Gene expression data for each rat were entered into Ingenuity software (combined 
in silico), which then ranked and calculated percent pathway impact (number of genes regulated/total 
number of genes in pathway) with a corresponding p-value for each treatment. Pathways impacted 
similarly  and  differentially  upon  exposure  to  the  respective  treatment  were  identified.  In  a  given 
analysis, the number of genes/probe sets represented depends on the statistical cutoffs and stringency 
parameters  for  each  separate  analysis,  resulting  in  a  slightly  different  magnitude  of  probe  sets 
presented. All analysis cutoffs are listed in each figure description. 
4. Conclusions 
The  results  here  describe  a  new  rat  model  of  IDR  using  TNFα  that  could  support  preclinical 
characterization of certain new drug candidates. Transcriptomic characterization of the model revealed 
a consistent hepatic response upon TNFα pretreatment. Further characterization of the model with the 
IDR-inducing drug TVX resulted in a sustained autoinduction of TNFα. This enhanced inflammatory 
response could be a component in the hepatotoxicity induced by TVX. 
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